Gossamer Bio(GOSS) - 2025 Q1 - Quarterly Results

Financial Performance - Cash, cash equivalents, and marketable securities totaled $258 million as of March 31, 2025[1] - Revenue from collaboration with Chiesi for the quarter ended March 31, 2025, was$9.9 million, including 6.6 million of cost reimbursement revenue[8] - Research and Development (R&D) expenses for the quarter were 38.0 million, compared to $32.4 million for the same period in 2024, representing an increase of 20.5$8.7 million, a decrease from $9.6 million for the same period in 2024[8] - Net loss for the quarter was$36.6 million, or $0.16 basic net loss per share, compared to a net loss of$41.9 million, or $0.19 basic net loss per share, for the same period in 2024[8] Clinical Trials - Enrollment for the ongoing registrational Phase 3 PROSERA Study in PAH patients is expected to complete in early June 2025, with over 350 patients anticipated[1] - Topline results from the PROSERA Phase 3 Study are expected to be announced in February 2026[1] - The Phase 3 SERANATA Study in PH-ILD patients is expected to activate clinical sites in the fourth quarter of 2025, with approximately 480 patients to be randomized[7] - The PROSERA Study has enrolled 343 patients to date, with a target of 350 participants[6] - The primary endpoint of the PROSERA Study is the change in six-minute walk distance (6MWD) from baseline compared to placebo at week 24[6]